An interesting publication appeared in the last issue of Phlebology journal. Researchers checked available literature to look at an effectiveness of pentoxifylline (PTX) in the treatment of venous ulcers, a known complication of chronic venous disease (CVD).
While venous ulcers affect around 2% of those with CVD, that figure becomes much more significant when we remember that nearly 1 in 3 adults show some signs of CVD. That’s a lot of people potentially at risk for this painful and persistent condition.
According to authors, compression therapy (such as compression stockings) has been so far the main form of treatment. While effective at managing symptoms, compression alone does not address the underlying varicose veins causing the problem, therefore closing incompetent superficial veins is also essential for a successful treatment.
Here at the Vein Centre, we’ve seen patients heal chronic ulcers often within a few weeks following laser ablation and sclerotherapy. These minimally invasive procedures treat the root cause of venous ulcers by targeting faulty veins, often with dramatic results. However, even if the procedure is successfully performed and our patient is disciplined with the compression regime, delayed healing of the ulcer is seen.
This is where Pentoxifylline can make a difference.
PTX: A Powerful Support Tool?
PTX is a medication with a long history in vascular medicine, primarily used to improve blood flow in people with poor circulation. More recently, researchers have been exploring its use as a supportive treatment for venous ulcers. In a recent meta-analysis, PTX was shown to:- Speed up ulcer healing when used alongside compression stockings
- Achieve ulcer healing in 62% of patients within 12 to 24 weeks
- Be most effective at a daily dose of 800 to 1200 mg
- Be well tolerated, with no significant side effects reported